Efavirenz, emtricitabine, and tenofovir and Erdafitinib
Determining the interaction of Efavirenz, emtricitabine, and tenofovir and Erdafitinib and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.ADJUST DOSE: Coadministration with moderate inducers of CYP450 2C9 or 3A4 may decrease the plasma concentrations and therapeutic effects of erdafitinib. The mechanism is induction of CYP450 2C9- or 3A4-mediated metabolism of erdafitinib, which has been shown to be metabolized by these isoenzymes. MANAGEMENT: According to the manufacturer, if a moderate CYP450 2C9 or 3A4 inducer is coadministered at the start of erdafitinib therapy, the recommended dose of erdafitinib should be administered. If a moderate CYP450 2C9 or 3A4 inducer is coadministered after the initial dose increase period, the dose of erdafitinib may be increased up to 9 mg once daily based on serum phosphate levels and tolerability. When a moderate CYP450 2C9 or 3A4 inducer is discontinued, the current dose of erdafitinib may be continued in the absence of erdafitinib toxicity. References "Product Information. Balversa (erdafitinib)." Janssen Products, LP, Horsham, PA.
Professional:ADJUST DOSE: Coadministration with moderate inducers of CYP450 2C9 or 3A4 may decrease the plasma concentrations and therapeutic effects of erdafitinib. The mechanism is induction of CYP450 2C9- or 3A4-mediated metabolism of erdafitinib, which has been shown to be metabolized by these isoenzymes.
MANAGEMENT: According to the manufacturer, if a moderate CYP450 2C9 or 3A4 inducer is coadministered at the start of erdafitinib therapy, the recommended dose of erdafitinib should be administered. If a moderate CYP450 2C9 or 3A4 inducer is coadministered after the initial dose increase period, the dose of erdafitinib may be increased up to 9 mg once daily based on serum phosphate levels and tolerability. When a moderate CYP450 2C9 or 3A4 inducer is discontinued, the current dose of erdafitinib may be continued in the absence of erdafitinib toxicity.
- "Product Information. Balversa (erdafitinib)." Janssen Products, LP, Horsham, PA.
Generic Name: efavirenz / emtricitabine / tenofovir
Brand name: Atripla
Synonyms: Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Efavirenz, emtricitabine, and tenofovir-Erelzi Prefilled Syringe
- Efavirenz, emtricitabine, and tenofovir-Erelzi Sensoready Pen
- Efavirenz, emtricitabine, and tenofovir-Erelzi Subcutaneous
- Efavirenz, emtricitabine, and tenofovir-Ergocalciferol
- Efavirenz, emtricitabine, and tenofovir-Ergocalciferol Capsules and Tablets
- Efavirenz, emtricitabine, and tenofovir-Ergocalciferol Solution
- Erdafitinib-Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate
- Erdafitinib-Efavirenz, lamivudine, and tenofovir
- Erdafitinib-Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate
- Erdafitinib-Effaclor Duo
- Erdafitinib-Effer-K
- Erdafitinib-Effer-K Tablets